Medexus to Present at Raymond James Human Health Innovation Conference
- U.S. stocks, dollar sluggish, all eyes on Fed meet this week
- Tesla (TSLA) Tops Q2 EPS by 49c, Revenues Beat
- Chinese Tech Stocks Crushed on Fresh Regulatory Pressure
- Nearly $1 Billion Bitcoin (BTC) Shorts Liquidated Today Amid Amazon (AMZN) Rumors
- Aon (AON) and Willis Towers Watson (WLTW) Mutually Agree to Terminate Combination Agreement
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Raymond James Human Health Innovation Conference on June 21st, 2021.
Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer, will present a Company overview and provide a business update. The presentation will be webcast live and available for replay on the Company’s website at www.medexus.com/en_US/investors/news-events.
Raymond James Human Health Innovation ConferenceDate: Monday, June 21, 2021 Time: 2:40 P.M. Eastern Time
In addition to the presentation, management will be participating in virtual one-on-one meetings throughout the conference. Interested investors should contact their Raymond James representatives to schedule a meeting.
Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.
For more information, please contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: firstname.lastname@example.org
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: email@example.com
Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email: firstname.lastname@example.org
Investor Relations (Canada):Tina ByersAdelaide CapitalTel: 905-330-3275E-mail: email@example.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Williams Rowland Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
- First Savings Financial Group, Inc. Reports Financial Results For the Third Fiscal Quarter Ended June 30, 2021
- Brookfield Infrastructure Partners Submits Written Consent to the TSX as Evidence of Brookfield Infrastructure Corporation Security Holder Approval of the Inter Pipeline Ltd. Offer and Share Issuance
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesRaymond James
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!